OMER Omeros Corp stock chart & analysis
Conviction 38HealthcareScan · Fri, Nov 13, 2026Omeros Corp (OMER) closed at $17.49 (-2.81%) on Nov 13, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 48, RS Rating 98, -17.7% from its 52-week high, +1.8% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why OMER moved
From the StockSetups movers recaps that covered OMER, newest first. A recap states what was known that day.
- Close+26.3%
Omeros filed a 10-Q (quarterly financial report) and an earnings-related 8-K with the SEC on August 12, indicating a quarterly earnings release was the catalyst.
Top Stock Movers Today — August 13, 2026: Why DFSC, ARX, CURI, IVDA & OMER Surged →
Financials as of Tue, Jun 30, 2026 · quarterly.
OMER technical analysis
Trend
OMER's moving averages are mixed — no clean uptrend or downtrend. It closed 4.3% below the 50-day ($18.27) and 27.0% above the 200-day ($13.77). ADX(14) at 12 points to a weak trend — more range than direction. It meets 7 of 8 trend-template criteria.
Momentum
RSI(14) is 48, in the bearish half of its range. MACD crossed above its signal line 2 sessions ago. Its RS Rating of 98 puts its weighted 12-month performance ahead of about 98% of the US market.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $17.2M a day on average. ATR(14) is $0.8967, 5.1% of price — its typical daily range. Chaikin Money Flow (0.16) shows accumulation.
Key levels
The chart pattern's support is $16.02 and its resistance $19.76. The 52-week range is $6.24 to $21.24; price is 17.7% below the high and 180.2% above the low. The VWAP anchored at the 52-week high is $18.40, above price.
Performance
OMER returned +3.3% (1 week), -7.0% (1 month), +0.7% (3 months), +42.7% (6 months), +153.8% (1 year), +1.8% (year to date).
About Omeros Corp
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Pharmaceutical Preparations · Listed 2009 · 175 employees
Insider activity
SEC Form 4 transactions in OMER · open-market 3 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Demopulos Gregory A MD Chairman, CEO & President · Performance Stock Option (right to buy) · 2026-10-28 | Grant | 500K | — | 2026-10-28 | 2026-10-30 |
Cancelmo Peter B VP, General Counsel · Common Stock · 2026-08-31 | Exercise | 25K | $74K | 2026-08-31 | 2026-09-01 |
Cancelmo Peter B VP, General Counsel · Common Stock · 2026-08-31 | Sell | 25K | $464K | 2026-08-31 | 2026-09-01 |
Cancelmo Peter B VP, General Counsel · Stock Option (Right to Buy) · 2026-08-31 | Exercise | 25K | — | 2026-08-31 | 2026-09-01 |
Cancelmo Peter B VP, General Counsel · Common Stock · 2026-08-28 | Exercise | 25K | $74K | 2026-08-28 | 2026-09-01 |
Cancelmo Peter B VP, General Counsel · Stock Option (Right to Buy) · 2026-08-28 | Exercise | 25K | — | 2026-08-28 | 2026-09-01 |
Cancelmo Peter B VP, General Counsel · Common Stock · 2026-08-28 | Sell | 25K | $466K | 2026-08-28 | 2026-09-01 |
HANISH ARNOLD C Director · Common Stock · 2026-08-27 | Exercise | 2.5K | $40K | 2026-08-27 | 2026-08-28 |
HANISH ARNOLD C Director · Common Stock · 2026-08-27 | Exercise | 7.5K | $110K | 2026-08-27 | 2026-08-28 |
HANISH ARNOLD C Director · Common Stock · 2026-08-27 | Sell | 5K | $94K | 2026-08-27 | 2026-08-28 |
SEC filings
EDGAR filings in OMER · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.